{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.8","upperLimit":"29","value":"24.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"DOR is the time from the date the patient's objective status is first noted to be PR or better to the earliest date of progression (PD=Increase of \\> 25% from lowest response value in Serum/Urine M-component) is documented. Treatment response was assessed using the International Myeloma Working Group uniform criteria. Complete response (CR)=Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow. Stringent complete response (sCR)=A CR plus normal FLC ratio and no clonal cells in bone marrow. Near complete response (nCR)=A CR, with the persistence of original monoclonal protein. Very good partial response (VGPR) =Serum and urine M-component detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-component plus urine M-component \\<100 mg per 24 h, Partial response (PR)=≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \\<200 mg per 24 h.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine 75 mg/m\\^2 IV day 1 and 2 Lenalidomide 25 mg PO days 1-21 Dexamethasone 40 mg PO or IV days 1, 8, 15, 22 Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Maximum Tolerated Dose, Dose Level 4"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study completion","title":"Duration of Response (DOR) (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}